So, it seems that Nanostring recently raised 70 Million despite having 100 Million cash at hand, possibly and hopefully for licensing of the prognostic test, which would make a lot of sense given the history with Nanostring.

"The recent offering including the over allotment added about $68.3 million to the company coffers which pushed their cash position over $158 million ($4.65/share cash). The company prospectus indicated the funds would be used to expand commercialization of products, fund operations, and to do further research and development, but the corporate presentation hints at a more exciting strategy. [...]"